UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed	d by the	Registrant ⊠	Filed by a party other than the Registrant $\ \square$							
Chec	ck the ap	opropriate box:								
	Prelin	Preliminary Proxy Statement								
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))									
	Definitive Proxy Statement									
\times	Defin	Definitive Additional Materials								
	Solici	Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12								
			Ultragenyx Pharmaceutical Inc. (Name of Registrant as Specified In Its Charter)							
			(Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)							
Payr	nent of	Filing Fee (Check the	propriate box):							
\boxtimes	No fe	fee required.								
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.									
	(1)	(1) Title of each class of securities to which transaction applies:								
	(2)	Aggregate number of securities to which transaction applies:								
		Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):								
	(4)	Proposed maximum a	regate value of transaction:							
	(5)	Total fee paid:								
	_	aid previously with preliminary materials. s box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid								
			us filing by registration statement number, or the Form or Schedule and the date of its filing.							
	(1)	(1) Amount Previously Paid:								
	(2)	Form, Schedule or Re	stration Statement No.:							
	(3)	Filing Party:								

(4) Date Filed:

M75926-P53094

*** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on July 10, 2014.

ULTRAGENYX PHARMACEUTICAL INC.



ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO, CA 94949

Meeting Information

Meeting Type: Annual Meeting **For holders as of:** May 16, 2014

Date: July 10, 2014 **Time:** 4:00 p.m., Pacific Time **Location:** Meeting live via the Internet-please visit www.virtualshareholdermeeting.com/RARE14.

The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit www.virtualshareholdermeeting.com/RARE14 and be sure to have the information that is printed in the box marked by the arrow → ▼ ★ (located on the following page).

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT FORM 10-K

How to View Online:

Have the information that is printed in the box marked by the arrow \rightarrow [located on the following page] and visit: www.proxyvote.com.

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) *BY INTERNET*: www.proxyvote.com 2) *BY TELEPHONE*: 1-800-579-1639

3) BY E-MAIL*: sendmaterial@proxyvote.com

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 26, 2014 to facilitate timely delivery.

— How To Vote -

Please Choose One of the Following Voting Methods

Vote By Internet:

Before The Meeting:

Go to *www.proxyvote.com*. Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions.

During The Meeting:

Go to *www.virtualshareholdermeeting.com/RARE14*. Have the information that is printed in the box marked by the arrow **XXXX XXXX** (located on the following page) available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

Voting Items

The Board of Directors recommends that you vote FOR the election of the nominee for director named below:

Nominee:

1a. Emil D. Kakkis, M.D., Ph.D.

The Board of Directors recommends you vote FOR Proposals 2, 3 and 4:

- 2. Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2014.
- 3. Reapproval of the Internal Revenue Code Section 162(m) provisions of the 2014 Incentive Plan.
- 4. Reapproval of the Internal Revenue Code Section 162(m) provisions of the Corporate Bonus Plan.